Search for jet extinction in the inclusive jet-pT spectrum from proton-proton collisions at s=8 TeV

Published by the American Physical Society under the terms of the Creative Commons Attribution 3.0 License. Further distribution of this work must maintain attribution to the author(s) and the published articles title, journal citation, and DOI.The first search at the LHC for the extinction of QCD jet production is presented, using data collected with the CMS detector corresponding to an integrated luminosity of 10.7  fb−1 of proton-proton collisions at a center-of-mass energy of 8 TeV. The extinction model studied in this analysis is motivated by the search for signatures of strong gravity at the TeV scale (terascale gravity) and assumes the existence of string couplings in the strong-coupling limit. In this limit, the string model predicts the suppression of all high-transverse-momentum standard model processes, including jet production, beyond a certain energy scale. To test this prediction, the measured transverse-momentum spectrum is compared to the theoretical prediction of the standard model. No significant deficit of events is found at high transverse momentum. A 95% confidence level lower limit of 3.3 TeV is set on the extinction mass scale

Searches for electroweak neutralino and chargino production in channels with Higgs, Z, and W bosons in pp collisions at 8 TeV

Searches for supersymmetry (SUSY) are presented based on the electroweak pair production of neutralinos and charginos, leading to decay channels with Higgs, Z, and W bosons and undetected lightest SUSY particles (LSPs). The data sample corresponds to an integrated luminosity of about 19.5 fb(-1) of proton-proton collisions at a center-of-mass energy of 8 TeV collected in 2012 with the CMS detector at the LHC. The main emphasis is neutralino pair production in which each neutralino decays either to a Higgs boson (h) and an LSP or to a Z boson and an LSP, leading to hh, hZ, and ZZ states with missing transverse energy (E-T(miss)). A second aspect is chargino-neutralino pair production, leading to hW states with E-T(miss). The decays of a Higgs boson to a bottom-quark pair, to a photon pair, and to final states with leptons are considered in conjunction with hadronic and leptonic decay modes of the Z and W bosons. No evidence is found for supersymmetric particles, and 95% confidence level upper limits are evaluated for the respective pair production cross sections and for neutralino and chargino mass values

The efficacy and safety of valproic acid medications with controlled active ingredient release in adults in real clinical practice from the position of pharmacokinetic and pharmacogenetic approaches

Objective: to analyze the efficacy and tolerability of sustained-release sodium valproate (SV) in adult patients with focal or generalized epilepsy in real clinical practice in three regions (Krasnoyarsk, Moscow, and Samara) of the Russian Federation. Patients and methods. The investigation enrolled adult patients with focal (n=63) or generalized (n=31) epilepsy who had received a stable dose of the drug alone (n=64 (68%)) or in combination with one of the antiepileptic drugs (AEDs): levetiracetam, lamotrigine, topiramate, or perampanel (n=30 (31.9%)) for at least one year. According to the brand name of drugs, their use frequency was as follows: Depakine® Chrono (61.7%), Convulex® (16%), Depakine® Chronosphere (9.6%), Valparine® XP (8.5%), and Encorate® Chrono (4.3%). Results. For a period of over one year, most patients with focal epilepsy (FE) (49.2%) and idiopathic generalized epilepsy (IGE) (67.7%) achieved a remission of seizures when they used moderate (1000 mg) and low (<1000 mg) daily doses of SV. Among the PE and IGE patients taking Depakine Chronosphere, the remission rate was highest, amounting to 100 and 75%, respectively. The efficacy of SV in both FE and IGE decreased in the following order: Depakine Chrono, Convulex, and Valparine XP. Clinical remission was achieved in none of the patients taking Encorate Chrono. The most common unwanted side reactions (USRs) were weight gain, menstrual disorders, tremor, and hair loss; however, their total frequency (16%) proved to be substantially lower than previously considered. The side effects were observed in one-half of the patients receiving a daily SV dose of 1000 mg and more, USRs were noted during combination therapy with SV medications and topiramate (n=5) or lamotrigine (n=2). USRs were frequently observed in the heterozygous carriers of the single nucleotide polymorphisms (SNPs) CYP2C9∗3 (27.3%) versus those who had the common (wild-type) allele variant CYP2C9∗1, but USRs were recorded mainly in the heterozygous carriers of CYP2C9∗3 and CYP2C9∗2 who received low daily doses of SV. The frequency of the CYP2C9 gene among SNPs proved to be highest: CYP2C9∗1/∗1 in 68 (72.3%) patients, CYP2C9∗2 in 14 (14.9%), and CYP2C9∗3 in 11 (11.7%). The compound heterozygous CYP2C9∗2/∗3 genotype was recorded in one (1.06%) case. The inadequate effect of AEDs requires therapeutic drug monitoring (TDM); and to rule out USRs calls for pharmacogenetic studies before or at the early stages of titration of SV, by determining its starting dosage, titration rate, and therapeutic dose. TDM and a pharmacogenetics study allow optimization of the personalized choice of AEDs

The efficacy and safety of valproic acid medications with controlled active ingredient release in adults in real clinical practice from the position of pharmacokinetic and pharmacogenetic approaches

Objective: to analyze the efficacy and tolerability of sustained-release sodium valproate (SV) in adult patients with focal or generalized epilepsy in real clinical practice in three regions (Krasnoyarsk, Moscow, and Samara) of the Russian Federation. Patients and methods. The investigation enrolled adult patients with focal (n=63) or generalized (n=31) epilepsy who had received a stable dose of the drug alone (n=64 (68%)) or in combination with one of the antiepileptic drugs (AEDs): levetiracetam, lamotrigine, topiramate, or perampanel (n=30 (31.9%)) for at least one year. According to the brand name of drugs, their use frequency was as follows: Depakine® Chrono (61.7%), Convulex® (16%), Depakine® Chronosphere (9.6%), Valparine® XP (8.5%), and Encorate® Chrono (4.3%). Results. For a period of over one year, most patients with focal epilepsy (FE) (49.2%) and idiopathic generalized epilepsy (IGE) (67.7%) achieved a remission of seizures when they used moderate (1000 mg) and low (<1000 mg) daily doses of SV. Among the PE and IGE patients taking Depakine Chronosphere, the remission rate was highest, amounting to 100 and 75%, respectively. The efficacy of SV in both FE and IGE decreased in the following order: Depakine Chrono, Convulex, and Valparine XP. Clinical remission was achieved in none of the patients taking Encorate Chrono. The most common unwanted side reactions (USRs) were weight gain, menstrual disorders, tremor, and hair loss; however, their total frequency (16%) proved to be substantially lower than previously considered. The side effects were observed in one-half of the patients receiving a daily SV dose of 1000 mg and more, USRs were noted during combination therapy with SV medications and topiramate (n=5) or lamotrigine (n=2). USRs were frequently observed in the heterozygous carriers of the single nucleotide polymorphisms (SNPs) CYP2C9∗3 (27.3%) versus those who had the common (wild-type) allele variant CYP2C9∗1, but USRs were recorded mainly in the heterozygous carriers of CYP2C9∗3 and CYP2C9∗2 who received low daily doses of SV. The frequency of the CYP2C9 gene among SNPs proved to be highest: CYP2C9∗1/∗1 in 68 (72.3%) patients, CYP2C9∗2 in 14 (14.9%), and CYP2C9∗3 in 11 (11.7%). The compound heterozygous CYP2C9∗2/∗3 genotype was recorded in one (1.06%) case. The inadequate effect of AEDs requires therapeutic drug monitoring (TDM); and to rule out USRs calls for pharmacogenetic studies before or at the early stages of titration of SV, by determining its starting dosage, titration rate, and therapeutic dose. TDM and a pharmacogenetics study allow optimization of the personalized choice of AEDs

CMS Physics Technical Design Report: Addendum on High Density QCD with Heavy Ions

This report presents the capabilities of the CMS experiment to explore the rich heavy-ion physics programme offered by the CERN Large Hadron Collider (LHC). The collisions of lead nuclei at energies $\sqrt{s_{NN}}= 5.5\,{\rm TeV}$ , will probe quark and gluon matter at unprecedented values of energy density. The prime goal of this research is to study the fundamental theory of the strong interaction \u2014 Quantum Chromodynamics (QCD) \u2014 in extreme conditions of temperature, density and parton momentum fraction (low- x ). This report covers in detail the potential of CMS to carry out a series of representative Pb-Pb measurements. These include "bulk" observables, (charged hadron multiplicity, low p T inclusive hadron identified spectra and elliptic flow) which provide information on the collective properties of the system, as well as perturbative probes such as quarkonia, heavy-quarks, jets and high p T hadrons which yield "tomographic" information of the hottest and densest phases of the reaction